ArticleMaterials today. Bio2025
Y-shaped trivalent aptamer for targeted visualization and tracking of reprogrammed astrocytes.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite extensive research into the diverse transformations and functions of astrocytes, conventional fluorescence immunohistochemistry for their distinct identification remains challenging and time-consuming, primarily due to the lack of cell surface binders specific to these glial cells. To address this limitation, we developed a specific and straightforward imaging strategy for primary astrocytes using cell surface-targeting aptamers. We identified a novel anti-astrocyte DNA aptamer (designated Ast17-30) through a 17-round cell-SELEX process incorporating magnetic-activated cell sorting, designed to bypass the technical hurdles of SELEX when applied to short-lived cells. To enhance binding affinity, we further engineered this aptamer into a Y-shaped trimer (Tri-ΔAst17-30), enabling clear discrimination between astrocytes and neurons. Consequently, the engineered trivalent aptamer facilitated rapid astrocyte-specific endocytosis within minutes due to its increased binding avidity. This capability enabled longitudinal monitoring of astrocyte conversion into induced neural precursor cells, observing moderate pro-inflammatory gene expression in their transcriptomic profiles. Furthermore, Tri-ΔAst17-30 bound strongly to astrocytic glioblastoma cells (U87MG), with minimal binding to glial glioblastoma cells (C6), confirming specificity for astrocytic tumor cells. Given the current absence of reliable live-astrocyte-specific imaging techniques, we propose that this trivalent anti-astrocyte DNA aptamer has potential for investigating developmental pathways and targeted therapy of these crucial glial cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.